

Opevesostat MK-5684 Areas of Interest

We are currently accepting proposals for the Oncology Investigator-Initiated Studies Program (IISP). This is a highly competitive review process; decisions are based on scientific/clinical merit, strategic fit, and feasibility.

The following guidance is provided to ensure a successful proposal:

- Please consult your local Research Medical Scientific Director (RMSD, US) or country Global Medical Affairs Field Medical liaison for proposal-specific guidance before submission to confirm alignment with IISP scope and interests.
- Please review www.clinicaltrials.gov to ensure your study is not already approved or ongoing and consult your RMSD or country-specific liaison regarding studies in development. Proposals duplicating or competing with Opevesostat MK-5684 registration trials will not be supported.
- Letters of Support are required for use of third-party funding
- Less experienced investigators are encouraged to work with a mentor prior to IISP submission. If a mentor is involved, please provide their CV and a detailed letter outlining the mentoring plan.
- Safety-only primary endpoint proposals are out of scope.
- Only MSD investigational agents specified in these Aols are available for IIS use.
- The Program requests that investigators specify how they will support diversity in enrollment, including but not restricted to traditionally underrepresented minorities/ethnic groups.

MISP Clinical Areas of Interest by Tumor Type

Androgen receptor (AR) expressing (by IHC) salivary gland tumors.

Studies of monotherapy as any line of treatment of recurrent/advanced disease.

Adrenal cortical carcinoma (ACC), both hormonally active and inactive.

Studies of monotherapy as any line of therapy for recurrent/advanced disease, including substitution of mitotane monotherapy in the first line setting where patients are intolerant of mitotane or progress while on treatment with mitotane monotherapy.